ReviewDrug safety2019
Drug-Induced Photosensitivity-An Update: Culprit Drugs, Prevention and Management.
Review in Drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 5 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Community sunbed use and photosensitivity reactions: a systematic review.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Pooled it
- Drug induced hyperpigmentation: systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification.European journal of medical research · 2023Pooled it
- Associations of thiazide use with skin cancers: a systematic review and meta-analysis.BMC medicine · 2022Pooled it
- Medicinal Plant Extracts and Natural Compounds for the Treatment of Cutaneous Lupus Erythematosus: A Systematic Review.Frontiers in pharmacology · 2022Pooled it
- Translating Exploratory Photoprotection Data Into Practical Clinical Guidance for IMID Patients.Photodermatology, photoimmunology & photomedicine · 2026Article
- Article
- UV Protection Habits and Preferences in Patients With Distinct Cutaneous Immune-Mediated Inflammatory Diseases.Photodermatology, photoimmunology & photomedicine · 2026Observational
- Sun Protection Advice for the South African Population for the Prevention and Management of Skin Diseases.International journal of dermatology · 2026Review
- Management ofCase reports in pediatrics · 2026Article
- [Clinical characteristics of trimethoprim-sulfamethoxazole-induced rash during treatment of pertussis in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Sun protection: a practical guide for health professionals.Australian prescriber · 2025Review
- Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.Current treatment options in oncology · 2025Review
- Oral Doxycycline Was a Safe and Feasible Treatment in Young Children With Neuroborreliosis.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Fluoroquinolones for Dermatologists: A Practical Guide to Clinical Use and Risk Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database.Scientific reports · 2025Article
- Photobiomodulation therapy.JADA foundational science · 2025Review
- Skin cancer prevention in the Polish population during the COVID-19 pandemic.Frontiers in public health · 2025Article
- Skin manifestations in diabetes-what is new?Frontiers in medicine · 2025Review
- Two Small Molecule Drugs with Topical Applications, Diflunisal and Naphazoline, and Their Potentially Toxic Photodegradants: Analysis by Chemical and Biological Methods.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photosensitive drug eruptions are cutaneous adverse events due to exposure to a medication and either ultraviolet or visible radiation. In this review, the diagnosis, prevention and management of drug-induced photosensitivity is discussed. Diagnosis is based largely on the history of drug intake and the appearance of the eruption primarily affecting sun-exposed areas of the skin. This diagnosis can also be aided by tools such as phototesting, photopatch testing and rechallenge testing. The mainstay of management is prevention, including informing patients of the possibility of increased photosensitivity as well as the use of appropriate sun protective measures. Once a photosensitivity reaction has occurred, it may be necessary to discontinue the culprit medication and treat the reaction with corticosteroids. For certain medications, long-term surveillance may be indicated because of a higher risk of developing melanoma or squamous cell carcinoma at sites of earlier photosensitivity reactions. A large number of medications have been implicated as causes of photosensitivity, many with convincing clinical and scientific supporting evidence. We review the medical literature regarding the evidence for the culpability of each drug, including the results of phototesting, photopatch testing and rechallenge testing. Amiodarone, chlorpromazine, doxycycline, hydrochlorothiazide, nalidixic acid, naproxen, piroxicam, tetracycline, thioridazine, vemurafenib and voriconazole are among the most consistently implicated and warrant the most precaution by both the physician and patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.